J.M.P.A. van den Reek

Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

Linda Davidson, J.M.P.A. van den Reek, Mariolina Bruno et al. · The Lancet Regional Health - Europe · 2021 · 118 citations · Full text

Medicine, Dermatology, Immunology +17

Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis

S.P. Menting, Emma Coussens, Mieke F. Pouw et al. · JAMA Dermatology · 2015 · 101 citations · Full text

Medicine, Dermatology, Pharmacotherapy +14

Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis

S.P. Menting, P.P.M. van Lümig, Anna-Christa Q. de Vries et al. · JAMA Dermatology · 2013 · 81 citations · Full text

Life Sciences, Dermatology, Immunology +17

Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t

Jeffrey Zweegers, J.M.P.A. van den Reek, P.C.M. van de Kerkhof et al. · British Journal of Dermatology · 2016 · 78 citations

Medicine, Pharmacology, Pharmacotherapy +13

Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis

Jorien van der Schaft, Klaziena Politiek, J.M.P.A. van den Reek et al. · British Journal of Dermatology · 2015 · 77 citations

Medicine, Dermatology, Pharmacotherapy +17